Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

An ocular implant is constructed of a clear, transparent, biologically compatible material and includes a hydrophilic outer surface configured for continuous attachment to a posterior surface of a cornea. The ocular implant has a first radius of curvature at initial attachment to the posterior surface of the cornea and a second radius of curvature at post-initial attachment to the posterior surface of the cornea. The first radius of curvature is different than the second radius of curvature. The ocular implant remains attached to the posterior surface of the cornea at both the first and second radii of curvature.

Systems and methods for wireless stimulation of biological tissue (e.g. nerves, muscle tissue, etc.) and, in one exemplary implementation, to therapy for glaucoma based on the wireless administration of energy to the eye of a mammalian subject (e.g. human, rodent, etc.) to reduce an elevated intraocular pressure (IOP) involving the use of a multi-coil wireless power transfer assembly. The multi-coil wireless power transfer assembly may be used alone or in combination with a stimulation coil that can be implanted in the eye of a mammalian subject or within a contact lens worn by a mammalian subject.

The present disclosure relates to an eye disease implant device, and an eye disease implant device according to an embodiment of the present disclosure includes a tube including a hollow portion through which aqueous humor is drained, wherein one or more wings extending in a direction different from a longitudinal direction of the tube are formed on a portion of an outer surface of the tube. Also, the eye disease implant device may further include a body including a receiving space into which an end of the tube is inserted. In this case, the end of the tube may be inserted into the receiving space to be coupled to the body, or detached from the receiving space to be separated from the body.

Delivery devices, systems and methods are provided for inserting an implant into an eye. The delivery or inserter devices or systems can be used to dispose or implant an ocular stent or implant, such as a shunt, in communication with a suprachoroidal space of the eye. The implant can drain fluid from an anterior chamber of the eye to a physiologic outflow path of the eye, such as, the suprachoroidal space or other portion of the uveoscleral outflow path. The delivery or inserter devices or systems can be used in conjunction with other ocular surgery, for example, but not limited to, cataract surgery through a preformed corneal incision, or independently with the inserter configured to make a corneal incision. The implant can be preloaded with or within the inserter to advantageously provide a sterile, easy-to-use package for use by an operator.

The present technology is directed to adjustable flow glaucoma shunts, systems, and methods for making and using such devices. In many of the embodiments described herein, the shunts include a drainage element configured to fluidly couple an anterior chamber of an eye and a target outflow location, such as a subconjunctival bleb space. The shunts can further include a flow control assembly coupled to the drainage element and configured to control the flow of fluid (e.g., aqueous) therethrough. The shunts can further include an outer membrane or bladder that encases the flow control assembly. The outer membrane can include a plurality of apertures that fluidly couple an interior of the outer membrane with an environment exterior to the outer membrane.

A glaucoma drainage device includes an elongated body extending axially from a distal end to a proximal end. The distal end forms a wedge with a leading distal edge. During implantation of the device into the suprachoroidal space of the eye, the wedge can facilitate penetration into and spreading open the tissue of the suprachoroidal space. The elongate body has one or more outer surfaces that define at least one open groove extending from at or near the proximal end towards the distal end of the body. With the distal end of the elongate body located in the suprachoroidal space of the eye and the distal end of the elongate body extending into the anterior chamber of the eye, the at least one open groove is configured such that aqueous humor flows along the open groove from the anterior chamber of the eye to the suprachoroidal space of the eye.

The present disclosure relates to intraocular implants for treating a condition of the eye, wherein the implant is configured to deliver a drug to the eye. The present disclosure also relates to methods of treating a condition of the eye by delivering a drug from intraocular implants to the posterior chamber (e.g., sulcus), iridocorneal angle, sclera, cornea, limbus, and vitreous.

An implantable delivery device for dispensing a medicament that includes a first microporous material that is bonded to a second microporous material. The first microporous material has a first microporous layer including a plurality of pores sized to permit tissue ingrowth and a second microporous layer including a plurality of pores sized to permit tissue ingrowth. The second microporous material has a third microporous layer including a plurality of pores sized to resist tissue ingrowth and a fourth microporous layer including a plurality of pores sized to permit tissue ingrowth. The second microporous layer is bonded to the third microporous layer to thereby form a reservoir for receiving the medicament. The first and second microporous materials are configured to meter a rate at which the medicament is dispensed from the reservoir when the delivery device is implanted.

An injector (1) for implanting a sensor implant (2) in the human or animal eye, in particular for the suprachoroidal implantation of a pressure sensor for the wireless measurement of the intraocular pressure, is improved in terms of rapid, complication-free, low-trauma and low-wear suprachoroidal implantation in that, to accommodate the sensor implant, the injector (1) has a substantially tubular injection chamber (8), the inner wall surfaces (9, 10) of which have a non-rotationally symmetrical cross section, preferably an oval or rectangular cross section, in that, at a free end, the injection chamber (8) is provided with an injection opening (13), through which, during implantation, the sensor implant (2) can slide out and slide into a sclera incision in the eye, wherein the inner wall surfaces (9, 10) of the injection chamber (8) enclose the likewise non-rotationally symmetrical cross section of the sensor implant (8) and prevent a rotation of the sensor implant (2) about an axis of rotation extending in the direction of the injection (11).